



Antonio Llombart Cussac, MD, PhD

Antonio Llombart, MD, PhD, is chairman of the Medical Oncology Service at the University Hospital Arnau de Vilanova in Valencia, Spain. He received his medical school training in Pamplona and Valencia, Spain; as well as his training in medical oncology at the University Clinic Hospital in Valencia. He performed a 4 years fellowship in the Breast Cancer Unit at Institute Gustave Roussy (Villejuif, France) focusing on new drugs (phase I and phase II studies). From 1997 to 2005, Dr Llombart was a member of the Department of Medical Oncology at the Instituto Valenciano de Oncologia. In 2003, he was promoted to the position of head of the Breast Cancer Research Unit. He obtained his PhD degree in breast cancer in 2005. From 2005 to 2010, Dr Llombart was the head of the Medical Oncology Service at the University Hospital HUAU in Lleida, Spain. In 2011 he returned to the Hospital Arnau de Vilanova in Valencia as Head of department of Medical Oncology and

professor of Clinical Oncology at the Universidad Catolica de Valencia.

Dr Llombart has been actively involved in the GEICAM and SOLTI Spanish groups for Breast Cancer, as well as many international cooperative groups and trials. He coordinates a clinical unit integrated by pharmacologists, surgeons, pathologists, and biologists working with cytotoxic and molecular agents both in human and animal models. His major present focus is on translational clinical trials and correlative science in the management of ER-positive breast cancer patients. In 2012, and in collaboration with other top oncologist, he co-founded an Academic Research Organization (MedSIR) that is leading a significant number of clinical trials and researches in several tumor diseases.

Dr Llombart Cussac has authored or co-authored over 100 publications, book chapters, and coaching and training materials. He also authored or co-authored abstracts and has contributed to many conferences, both national and international. He has served as a scientific expert in several scientific committees, as a board member of Sociedad Española de Oncología Médica, and as scientific director and president of the SOLTI group.